|
 The Federal Trade Commission had asked the company for information
months ago as part of a preliminary investigation, a company
spokesperson said in an email.
The company did not provide any further details on the investigation
but said suggestions it took any inappropriate or unlawful actions
to prevent generic competition was "without merit."
Mylan has come under fire for raising the price of a pair of EpiPens
to $600 from $100 in 2008 and listing it with Medicaid as a generic
product even though it is listed with the U.S. Food and Drug
Administration as a branded product. Companies pay smaller rebates
to Medicaid for generics.
"The epinephrine auto-injector market is and always has been
competitive, with multiple products competing on the market since we
acquired EpiPen Auto-Injector," Mylan said in its statement on
Monday.
[to top of second column] |
Bloomberg had first reported the news.
(Reporting by Anya George Tharakan in Bengaluru; Editing by
Saumyadeb Chakrabarty)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
